Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved. 31 - 2 Parkinson’s.

Slides:



Advertisements
Similar presentations
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Advertisements

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 15 Cholinesterase Inhibitors and Their Use in Myasthenia Gravis.
Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Drugs for Parkinson’s Disease & Psychotherapeutics NSG 106 Pharmacotherapeutics.
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Anticonvulsants and Antiparkinsonism Drugs Chapter 5.
Chapter 18 Agents that Dilate Blood Vessels. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Coronary.
Chapter 29 Central Nervous System Stimulants Used to Treat Attention Deficit Hyperactivity Disorder and Agents Used to Treat Alzheimer’s Disease.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Chapter 17 Cardiac Stimulants and Depressants. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
Anti Parkinson's Drugs Parkinsonism
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
PARKINSON’S DISEASE. ETIOLOGY 1) Idiopathic 2)Exposure to : neurotoxin Oxidative stress Drugs Oxidative stress Drugs 3)Genetic factors. 3)Genetic factors.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 13 Drugs Affecting the Autonomic Nervous System.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
Chapter 34 The Autonomic Nervous System. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Autonomic.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
By Prof. Hanan Hagar Pharmacology unit Medical College.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 23 DRUGS FOR NEUROLOGIC DISORDERS: PARKINSONISM AND ALZHEIMER’S DISEASE.
Parkinson's Disease ILOs
Drugs in parkinsonism ilos
Neurotransmissions in the Central Nervous System.
Dr. Laila M. Matalqah Ph.D. Pharmacology PHARMACOLOGY OF CNS part 1 General Pharmacology M212.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 32 Anticonvulsants. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Epilepsy An electrical.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
Pharmacologic Management of parkinsonism
Drugs for Degenerative Diseases of the Nervous System.
Drug Therapy for Parkinson’s Disease
Chapter 25 Emetics and Antiemetics. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Emetics Agents.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Pharmacology Nursing C ONTINUE CNS D RUGS Lecture 7.
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinsonism.
DRUGS FOR PARKINSONISM
Drugs for Neurologic Disorders: Parkinsonism and Alzheimer’s Disease
Drugs of Anti-Parkinson’s disease
Central Nervous System Drugs: Part 1 Autonomic Nervous System Drugs Drugs Used to treat Seizures Drugs Used to treat Parkinson’s Disease Analgesics.
Drugs for Parkinson’s Disease
Jeopardy Final Jeopardy Barbiturates $100 $100 $100 $100 $100 $200
Treatment of Parkinson’s disease
Central Nervous System
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Antiparkinsonian drugs Presented by K.Lakshmi Department of pharmacology Assistant professor SSPC.
Drugs for Degenerative Diseases of the Nervous System
Emetics and Antiemetics
Classification of Epilepsy (p. 227)
Neuroleptic drugs.
Antipsychotic Agents & Schizophrenia
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Presentation transcript:

Chapter 31 Anti-Parkinson Agents

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s Disease A neurological disorder characterized by:  Muscle tremors  Muscle rigidity  Lack of coordination  Drooling  Shuffling gait  Postural changes (continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s Disease Imbalance of dopamine and acetylcholine levels in the brain Levels of other neurological chemical decrease:  Gamma-aminobutyric acid (GABA)  Serotonin  Norepinephrine (continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Classes of Anti-Parkinson Agents Dopaminergic agents Anticholinergic agents Catechol-O-methyltransferase inhibitors

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Levodopa Dopaminergic agent Most effective drug treatment Acts peripherally Rapidly converts to dopamine Symptoms subside or disappear (continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Levodopa Therapeutic effects  Therapeutic intensity varies  Dosage dependent Adverse effects  Nausea and vomiting  Orthostatic hypotension  Cardiac arrhythmias (continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Carbidopa/Levodopa (Sinemet) Carbidopa prevents levodopa from being broken down in the peripheral circulation Improves neurological-skeletal muscle activity Combining these agents reduces the required Levodopa dose by 25%  Given in Carbidopa, 10 mg / Levodopa,100 mg dose

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Amantadine (Symmetrel) Treats viral disorders such as influenza Acts as an anti-Parkinson agent; it exerts an additive effect on Levodopa  Increases CNS dopamine concentration

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Anticholinergic Agents Reduces excessive cholinergic brain activity  Example: trihexyphenidyl (Artane)  Used for clients with minimal symptoms  Adjunct with other agents Caution: narrow-angle glaucoma (continues)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Anticholinergic Agents Apomorphine (Apokyn)  Morphine-like substance  Old, but new  No analgesic or addictive qualities  Increases dopamine activity (continued)

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Newest class of anti-Parkinson drug agents Treats clients with history of poor response to levodopa  Sustains dopaminergic levels  Brain remains stimulated (continues) Catechol-O-Methyltransferase Inhibitors

Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Catechol-O-Methyltransferase Inhibitors Adverse effects  Liver failure  Dyskinesia  Orthostatic hypotension  Dystonia  Somnolence  GI irritation (continued)